The association of calcium channel blockers with beta-cell function in type 2 diabetic patients: A cross-sectional study

Dong Zhao, Yu Cao, Cai-Guo Yu, Sha-Sha Yuan, Ning Zhang, Yuan-Yuan Zhang, Jan A. Staessen, Ying-Mei Feng*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)

Abstract

Type 2 diabetes mellitus (T2DM) patients are often accompanied with hypertension. However, the association of antihypertensive drugs with beta-cell function has not been well studied. To investigate this question, the authors performed a cross-sectional study involving 882 hypertensive T2DM patients. To assess beta-cell function, patients were given 75g glucose orally and C-peptide levels before and 1, 2, and 3 hours after glucose intake were measured. Homa-beta was computed by Homeostasis Model Assessment model to evaluate beta-cell function using fasting C-peptide and glucose levels in the plasma. Multivariable-adjusted analysis was performed to evaluate the association of antihypertensive drugs with C-peptide levels, HbA1c, and Homa-beta. Among 882 hypertensive patients, 547 (62.0%) received antihypertensive treatment. Multivariate-adjusted analysis demonstrated that use of calcium channel blockers (CCBs) was negatively associated with HbA1c levels (CCBs: 0.95 [95% CI: 0.92-0.98], P = 0.002). Our data further illustrated that the C-peptide levels before and 1, 2, and 3 hours of OGTT were 1.10-, 1.18-, 1.19-, and 1.15-fold increase in T2DM patients taking CCBs (P = 0.084 for fasting C-peptide levels; P = 0.11). In conclusion, CCB treatment was negatively associated with HbA1c levels but positively associated with beta-cell function in hypertensive T2DM patients, implying that CCBs could be considered to treat hypertensive T2DM patients with reduced beta-cell function.

Original languageEnglish
Pages (from-to)638-647
Number of pages10
JournalJournal of Clinical Hypertension
Volume21
Issue number5
DOIs
Publication statusPublished - May 2019

Keywords

  • calcium channel blocker
  • hypertension
  • inhibitor of renin-angiotensin-aldosterone system
  • type 2 diabetes mellitus
  • beta-cell function
  • HYPERTENSIVE PATIENTS
  • RECEPTOR BLOCKADE
  • ANGIOTENSIN-II
  • ER STRESS
  • RENIN
  • ALDOSTERONE
  • INHIBITION
  • PREVALENCE
  • PROTECTION
  • SYSTEM

Cite this